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Necrosis and apoptosis represent two pathogenetically distinct types of cell death. Necrosis is associated with
pathologic conditions while apoptosis is a physiological process of programmed cell death, which is associated
with normal tissue growth and is frequently impaired in various forms of cancer. Tumor necrosis and apoptotic
index (AI) have been previously evaluated as prognostic biomarkers in lung cancer, but their exact clinical value
remains unclear. The aim of this study was to perform a systematic review of the MEDLINE literature on the
prognostic significance of these histopathological markers in patients with non-small cell lung carcinoma (NSCLC).
Although a substantial body of evidence suggests that tumor necrosis may be a strong predictor of aggressive
tumor behavior and reduced survival in patients with NSCLC, the independent prognostic value of this biomarker
remains to be firmly established. Furthermore, previous data on the prognostic significance of apoptotic index in
NSCLC are relatively limited and largely controversial. More prospective studies are necessary in order to further
validate tumor necrosis and AI as prognostic markers in NSCLC.
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Lung cancer remains the leading cause of death from
cancer worldwide and one of the 10 leading causes of death
from all causes (Murray & Lopez 2013). The prognosis of
lung cancer remains poor. Even in the cases of resected
tumors, recurrence rates are high. The identification of
independent and reproducible prognostic factors may
affect therapeutic decisions and influence clinical research.
Histopathologic features are commonly evaluated for their
potential use as prognostic factors. Tumor necrosis and the
apoptotic index (i.e. the proportion of apoptotic cells in
tumor specimens) are two such features.
Cells maintain homeostasis by regulating a wide range
of both intracellular and extracellular microenvironmental
parameters. Various stress factors can force cells to
adapt through hypertrophy, hyperplasia, atrophy or metapla-
sia (Kumar et al. 2007), achieving stability and -sometimes-
normal function. If the external stress factor is persistent or
severely harmful, the cells’ adjustment mechanisms are not
sufficient to prevent cell injury. In that case, cell changes* Correspondence: ksyrigos@med.uoa.gr
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in any medium, provided the original work is pmay be partially reversible, and there is always the pos-
sibility for a cell to overcome the stressful condition
and survive without residual malfunction. On the other
hand, a long-standing harmful stressor can lead to irre-
versible damage and cell death.
There are two distinct types of cell death in terms of
pathogenesis: necrosis and apoptosis. Necrosis is always
associated with abnormal processes, such as exposure to
toxins, various infections, trauma and ischemia. Cell
injury leads to membrane dysfunction, leak of lysosomic
enzymes in the cytoplasm and, finally, cell digestion
(Poon et al. 2010). Secondary inflammation occurs in
the surrounding tissue, and neutrophilic enzymes further
contribute to the evolving necrosis (Proskuryakov & Gabai
2010). Depending on the causative agent, several different
types of necrosis have been described. Specifically, in case
of a tumor mass, the pattern of coagulative necrosis is the
most common. It is mainly caused by tissue hypoxia due
to rapid tumor growth, insufficient neovascularization,
compression and thrombotic obstruction of adjacent ves-
sels. Resulting necrosis is characterized by the presence of
dead cells in the form of anucleate “ghost cells’, but with
preservation of the tissue architecture (Kumar et al. 2007).
Coagulative necrosis is often massive and grossly evidents an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Table 1 Studies on the prognostic role of necrosis in
patients with non-small cell lung carcinoma (listed in
chronological order)
Ref no Type Year No of patients
Lipford et al. (1984) retrospective 1984 173
Elson et al. (1988) retrospective 1988 47
Lee et al. (1989) retrospective 1989 30
Roeslin et al. (1991) retrospective 1991 97
Roberts et al. (1992) retrospective 1992 87
Shahab et al. (1992) retrospective 1992 28
Tormanen et al. (1995) retrospective 1995 75
Kessler et al. (1996) retrospective 1996 593
Goldstein et al. (1999) retrospective 1999 218
Swinson et al. (2002) retrospective 2002 178
Poleri et al. (2003) retrospective 2003 53
Khan et al. (2004) retrospective 2004 98
Rena et al. (2007) retrospective 2007 87
Inoue et al. (2008) retrospective 2008 97
Cho et al. (2008) prospective 2008 55
Nia et al. (2010) retrospective 2010 239
Kilinçgün et al. (2010) N/A 2010 152
Park et al. (2011) retrospective 2011 201
Pataer et al. (2012) retrospective 2012 358
Tantraworasin et al. (2013) retrospective 2013 227
N/A: Not Available.
Table 2 Studies on the prognostic role of apoptosis in
patients with non-small cell lung carcinoma (listed in
chronological order)
Ref no Type Year No of patients
Tormanen et al. (1995) retrospective 1995 75
Komaki et al. (1996) retrospective 1996 173
Tanaka et al. (1999) retrospective 1999 236
Matturi et al. (1999) N/A 1999 38
Langendijk et al. (2000) retrospective 2000 161
Gorgoulis et al. (2000) retrospective 2000 63
Hwang et al. (2001) retrospective 2001 68
Puglisi et al. (2002) retrospective 2002 N/A
Dworakowska et al. (2009) retrospective 2009 170
N/A: Not Available.
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described in a minority of benign tumors.
In contrast to necrosis, apoptosis is a physiological
phenomenon that occurs spontaneously and is associated
with normal tissue growth. It is an active process, linked to
specific molecular pathways (Edinger & Thompson 2004).
It discards independent, severely injured cells without caus-
ing an inflammatory host reaction. Factors such as hypoxia,
irradiation or chemotherapeutic agents can cause irrevers-
ible DNA damage and activate the apoptotic process,
thus diminishing the risk of a possibly harmful muta-
tion and malignant transformation (Kumar et al. 2007).
A characteristic feature of cancer cells is their ability to
escape apoptosis.
The prognostic significance of tumor necrosis and
apoptotic index (AI) in NSCLC has been previously in-
vestigated in several clinicopathological studies spanning
the past three decades. Nevertheless, most of these previous
reports have yielded variable or even controversial results.
The aim of this study was to perform a review of the
MEDLINE literature in an attempt to determine the
exact clinical value of tumor necrosis and apoptotic
index (AI) as prognostic biomarkers in NSCLC. We re-
trieved 28 papers, investigating the prognostic significance
of necrosis and/or apoptosis in patients with primary
NSCLC (Tables 1 and 2) (Lipford et al. 1984; Elson et al.
1988; Lee et al. 1989; Roeslin et al. 1991; Roberts et al.
1992; Shahab et al. 1992; Tormanen et al. 1995; Kessler
et al. 1996; Goldstein et al. 1999; Swinson et al. 2002;
Poleri et al. 2003; Khan et al. 2004; Rena et al. 2007;
Inoue et al. 2008; Cho et al. 2008; Sardari Nia et al.
2010; Kiliçgün et al. 2010; Park et al. 2011; Pataer et al.
2012; Tantraworasin et al. 2013; Komaki et al. 1996;
Tanaka et al. 1999; Matturi et al. 1999; Langendijk et al.
2000; Gorgoulis et al. 2000; Hwang et al. 2001; Puglisi
et al. 2002; Dworakowska et al. 2009). Studies on apoptosis-
related genes were excluded.
Review
Tumor necrosis
Tumor necrosis is a histopathologic feature commonly
found in resected pulmonary tumors. The identification
of tumor necrosis as an independent and significant
prognostic factor could affect therapeutic decisions
and dictate the necessity of adjuvant chemotherapy in
selected cases. Thus, in the last decades, the prognostic
significance of necrosis in resectable non-small cell
carcinomas has been assessed by many investigators in
a series of, mostly retrospective, studies investigating
the impact of these histological features on survival of
patients. (Lipford et al. 1984; Elson et al. 1988; Lee et al.
1989; Roeslin et al. 1991; Roberts et al. 1992; Shahab
et al. 1992; Tormanen et al. 1995; Kessler et al. 1996;
Goldstein et al. 1999; Swinson et al. 2002; Poleri et al.2003; Khan et al. 2004; Rena et al. 2007; Inoue et al.
2008; Cho et al. 2008; Sardari Nia et al. 2010; Kiliçgün et al.
2010; Park et al. 2011; Pataer et al. 2012; Tantraworasin
et al. 2013).
In the majority of these previous studies, clinical,
pathological and follow up data were correlated to tumor
necrosis. In 7 studies (Elson et al. 1988; Shahab et al. 1992;
Goldstein et al. 1999; Poleri et al. 2003; Rena et al. 2007;
Cho et al. 2008; Tantraworasin et al. 2013), patients of
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stage III were the target group in a single report (Lee
et al. 1989) and clinical stage was not included in the
statistical evaluation of one paper (Roberts et al. 1992).
In the remaining studies (Lipford et al. 1984; Roeslin
et al. 1991; Tormanen et al. 1995; Kessler et al. 1996;
Swinson et al. 2002; Khan et al. 2004; Inoue et al. 2008;
Sardari Nia et al. 2010; Kiliçgün et al. 2010; Park et al.
2011; Pataer et al. 2012) patients of various clinical stages
(I, II, III) were included. Standard morphological criteria
were used for the diagnosis and subclassification of NSCLC
tumors. Adenocarcinomas followed by squamous cell car-
cinomas were the prevailing histological types.
In most of these studies, the presence and extent of
microscopically recognized necrotic areas was semi
quantitatively evaluated. There is, however, a great dis-
crepancy in the exact scale used for this measurement.
In a minority of studies only the presence or absence
of necrosis was recorded and no measurement scale
was used (Rena et al. 2007; Inoue et al. 2008). Other
researchers arbitrarily used the percentage of necrosis
in the examined neoplastic tissue – more than 50%
(Shahab et al. 1992), more than one third (Khan et al. 2004)
more than 20% (Roeslin et al. 1991) and more than
10% (Kessler et al. 1996) of the tissue – as a criterion
for classifying the tumor as necrotic. Histological sections
from the periphery of the tumor were examined in one
study (Swinson et al. 2002) evaluating the influence of the
tumor microvasculature on tumor necrosis. There was no
sampling from the rest of the neoplastic mass in order
to avoid the bias of assessing necrosis secondary to
acute infarction. In eight studies (Lipford et al. 1984;
Roeslin et al. 1991; Shahab et al. 1992; Goldstein et al.
1999; Poleri et al. 2003; Khan et al. 2004; Inoue et al.
2008; Sardari Nia et al. 2010), no correlation of tumor
necrosis with survival was found at univariate statistical
analysis; in contrast, the prognostic significance of necro-
sis was statistically established in seven other retrospective
studies (Elson et al. 1988; Roberts et al. 1992; Tormanen
et al. 1995; Cho et al. 2008; Kiliçgün et al. 2010; Park et al.
2011; Pataer et al. 2012).
Kessler et al. (Kessler et al. 1996) previously reported
that tumor necrosis was associated with a poor overall
survival in univariate statistical analysis, but not in
multivariate analysis, where only N stage, blood vessel
invasion and the T stage were identified as significant
prognostic factors. In another study by Törmänen
et al. (Tormanen et al. 1995) it was concluded that
patients with squamous cell carcinoma showing >20%
necrosis had a shorter survival compared to patients
with non-necrotic tumors. This finding was confirmed
both in univariate and multivariate statistical analyses,
while no such correlation was found in cases of lung
adenocarcinomas.Extensive tumor necrosis was found to be of inde-
pendent prognostic value in a study of Swinson et al.
(Swinson et al. 2002), and the authors concluded that
in patients with lung cancer of clinical stage I and II,
necrosis was useful in improving the predictive power
of the TNM staging system. However, the prognostic value
of this histological parameter was diminished in cases of
patients with clinical stage III, while no association was
found between tumor necrosis and angiogenesis. A dismal
prognosis of NSCLC patients with tumor necrosis was
demonstrated by Kiliçgün et al. (Kiliçgün et al. 2010), both
in in univariate and multivariate analysis, and the authors
proposed adjuvant chemotherapy to be included in the
treatment protocol of all patients with tumor necrosis,
irrespectively of clinical stage. Tumor necrosis was found
to be a significant negative predictor of survival in a study
by Elson et al (Elson et al. 1988). This was confirmed
by Shahab et al (Shahab et al. 1992) in a subsequent
morphometric analysis of 28 surgically resected tumors
from patients with NSCLC.
Necrosis has been previously correlated with tumor
recurrence in seven studies (Lee et al. 1989; Kessler
et al. 1996; Swinson et al. 2002; Inoue et al. 2008; Sardari
Nia et al. 2010; Park et al. 2011; Tantraworasin et al. 2013)
and with metastatic disease in three studies (Lee et al. 1989;
Roeslin et al. 1991; Swinson et al. 2002). Inoue et al.
(Inoue et al. 2008) reported that microscopic necrosis
constituted a significant prognostic factor for tumor
recurrence in univariate, but not in multivariate analysis.
However, a significant correlation of microscopic necrosis
with nodal involvement, which was found to be an inde-
pendent predictor for postoperative recurrence in multi-
variate analysis, was also demonstrated in the latter study.
In another study by Park et al. (Park et al. 2011), tumor
necrosis was found to be a significant adverse risk factor
for recurrence, both in univariate and in multivariate
analysis, and was also correlated with reduced overall
survival in univariate analysis. Finally, Tantraworasin et al.
(Tantraworasin et al. 2013) identified tumor necrosis
along with intratumoral blood vessel invasion, tumor
diameter >5 cm and nodal involvement as independent
prognostic factors for tumor recurrence, and further
reported a positive correlation between tumor necrosis
and tumor size (64% of tumors >5 cm in diameter had
necrosis in comparison to 30% of tumors <5 cm).
Apoptotic index
Previous data on the prognostic significance of apoptotic
index in NSCLC are rather limited and mostly controver-
sial. Tanaka et al. (Tanaka et al. 1999) calculated the AI
using the TUNEL method in a series of surgically resected
NSCLCs. Multivariate analysis showed that a moderate
AI value predicted a poor survival, while prognosis was
relatively good in the lowest-AI group. Interestingly, the
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that was explained by the hypothesis that intense apoptosis
overcomes cell proliferation and retards tumor growth.
Similar results were observed by other researchers as well,
indicating that high AI may be a marker of favorable prog-
nosis in NSCLC (Matturi et al. 1999; Hwang et al. 2001).
Matturri et al (Matturi et al. 1999) found that high AI
values were associated with improved survival in patients
with NSCLC, while Hwang et al (Hwang et al. 2001)
reported that a low level of spontaneous apoptosis in
pretreatment histology predicted a poor prognosis for
radiation-treated NSCLC patients.
In contrast to these findings, Tormanen et al. (Tormanen
et al. 1995) reported that an AI higher than 1.5% con-
stituted an independent prognostic factor of shortened
survival. In another study by Langendijk et al (Langendijk
et al. 2000), high AI was associated with worse local
control, more distant metastases and a significantly worse
overall survival in patients with inoperable NSCLC treated
with high-dose radiotherapy. Furthermore, Dworakowska
et al (Dworakowska et al. 2009) found that NSCLC pa-
tients with very high AI values combined with very high
PCNA (proliferating cell nuclear antigen) labeling index
had a particularly poor prognosis and concluded that
joint analysis of several apoptosis, proliferation and cell
cycle regulation biomarkers may provide more useful
prognostic information as compared to AI alone. On
the other hand, other researchers failed to reveal any
association between AI and survival in patients with
NSCLC (Gorgoulis et al. 2000). In the study by Puglisi et al
(Puglisi et al. 2002), AI alone had no significant impact on
survival, but the combination of low AI and high prolif-
eration activity (high MIB-1 index) was associated with
a worse clinical outcome both in univariate and in
multivariate analysis. Interestingly, in another study by
Komaki et al (Komaki et al. 1996), although apoptosis
did not predict survival or distant metastases among all
patients with stage N1 NSCLC, high apoptosis predicted
significantly better survival in patients with squamous
carcinomas (SQ) and significantly worse survival in
patients with adenocarcinomas/large cell carcinomas.
(AC/LC). Therefore, the authors of the latter study
suggested that pretreatment levels of apoptosis might be
useful for predicting treatment outcome and metastatic
incidence of AC/LC, respectively, when these different
lung cancer subtypes are separately analyzed.
Conclusions
Although several previous clinicopathological studies have
demonstrated that tumor necrosis may be associated with
an aggressive tumor behavior and reduced survival of
patients, the independent prognostic significance of this
biomarker in NSCLC has not been firmly established yet.
Furthermore, these previous results should be interpretedwith caution and viewed in light of certain limitations,
mainly including the small sample size and retrospect-
ive nature of most series, the variable distribution of
the clinicopathological and treatment characteristics of
the studied populations as well as the discrepancy in the
criteria used by different research groups to define the pres-
ence and extent of microscopically recognized necrotic
tissue. Nevertheless, it should be emphasized that in a
limited number of studies with a significantly large sample
size, necrosis was statistically recognized as an indisputable
prognostic factor in multivariate analysis.
With regard to the prognostic significance of apoptotic
index in NSCLC, previous clinicopathological studies
have yielded contradictory and mixed results. Different
research groups have reported that a high apoptotic rate
may be associated with either shorter or longer survival,
while other studies have failed to reveal any statistically sig-
nificant correlation between AI and prognosis. As previ-
ously suggested, these contradictory reports may reflect the
fact that the apoptotic process is also influenced by a variety
of other prognostic biomarkers, including apoptosis regu-
lating proteins, suppressor oncogene products and a var-
iety of other markers involved in cell cycle regulation or
proliferative activity of tumors (Dobashi et al. 2004).
Most importantly, the clinical, histological and molecular
heterogeneity of lung carcinomas grouped under the term
NSCLC may also explain, at least to a certain degree, the
failure of previous studies to obtain consistent and repro-
ducible results on the prognostic significance of AI in this
form of cancer.
Carefully designed studies with strict criteria concerning
the amount of tumor examined and the exact determin-
ation of the percentage of the necrotic tissue must be
carried out prospectively in the future in order to eligi-
bly define the precise role of necrosis in the final out-
come of patients with resectable NSCLC. In addition,
the correlation of tumor necrosis with factors such as
tumor size, blood vessel invasion, lymphatic invasion
and degree of tumor differentiation needs further in-
vestigation. Larger studies are also required to high-
light the exact role of apoptosis in the determination of
the overall survival of patients with NSCLC. Unique
histological methodology, proper selection of patients and
high statistical power of prospective studies are expected
to contribute to the precise definition of the prognostic
value of necrosis and apoptosis.
With the advent of patient-tailored targeted therapies
in oncology, the need for more accurate risk stratifica-
tion of patients and improved prediction and monitoring
of response to treatment has become more pronounced
(Ulivi & Silvestrini 2013). Development of novel targeted
agents for NSCLC, modulating pathways involved in cell
proliferation, apoptosis, angiogenesis and invasion, is now
underway, holding promise for a significant improvement
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2007). In this regard, carefully selected biomarkers, includ-
ing apoptosis-related markers such as the AI, may serve in
the future not only for diagnosis or prognosis of NSCLC,
but also as tools to determine if a new agent is successfully
targeting neoplastic cells or not in each individual patient,
thus guiding optimal decision-making for personalized
therapeutics (Diaz et al. 2008).
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